MPNs

Panelists discuss how to monitor patients on JAK inhibitors, including blood count checks every 1 to 2 weeks initially, baseline spleen imaging with follow-up at 3 to 6 months, and symptom burden assessment.

Panelists discuss how to select among the four available JAK inhibitors (Ruxolitinib, Fedratinib, Pacritinib, and Momelotinib) based on patient-specific factors such as anemia, thrombocytopenia, and symptom burden.

New findings reveal that combining erythropoiesis-stimulating agents with ruxolitinib maintains efficacy in treating myelofibrosis-related anemia.

Asciminib shows superior tolerability over nilotinib in newly diagnosed CML-CP patients, reducing treatment discontinuation due to adverse effects significantly.

During a live event, Mojtaba Akhtari, MD, discussed the goals and treatment approach for patients with low-risk polycythemia vera.

David Andorsky, MD, discusses efficacy and safety findings from the ASC2ESCALATE study of asciminib in chronic myeloid leukemia.

Panelists discuss how JAK inhibitor therapy can benefit patients with intermediate-1–risk myelofibrosis despite being studied primarily in higher-risk patients in the COMFORT and JUMP trials.

Panelists discuss how risk stratification, symptom burden, and splenomegaly guide treatment decisions for a 68-year-old woman with intermediate-risk myelofibrosis who isn’t interested in transplant.

A groundbreaking study reveals rusfertide's potential to transform polycythemia vera treatment, reducing phlebotomy needs and improving patient quality of life.

In the VERIFY study, rusfertide significantly improved clinical responses vs placebo in polycythemia vera, offering a potential new therapy in the space.

Luspatercept significantly improved red blood cell transfusion independence duration and overall survival in ESA-naive, lower-risk MDS patients vs epoetin alfa.

During a live event, Christopher Benton, MD, discussed treatment of myelodysplastic syndromes like luspatercept and imetelstat as alternatives to ESAs.

In part 2, experts discuss optimizing the use of JAK inhibitors for patients with myelofibrosis.

During a live event, Karen Seiter, MD, discussed the role of the JAK/STAT pathway in myeloproliferative neoplasms and the use of ruxolitinib to treat myelofibrosis.

The FDA granted fast track status to givinostat for treating high-risk polycythemia vera, supporting its potential shown in the ongoing phase 3 GIV-IN PV trial.

During a live event, Mark J. Fesler, MD, and participants discussed selection and timing of initiation of JAK inhibitor therapy for myelofibrosis.

In part 1, experts explores how assessing individual risk factors is crucial in selecting the appropriate JAK inhibitor for patients with myelofibrosis.

During a live event, Mark J. Fesler, MD, and participants discuss next steps for a 68-year-old patient with intermediate-risk myelofibrosis.

Bexmarilimab and azacitidine showed continued tolerability and a high overall response rate in relapsed/refractory higher-risk myelodysplastic syndromes in a phase 2 study.

Akriti Jain, MD, discussed how emerging data on non-ABL1 mutations is reshaping chronic myeloid leukemia management.

The investigational immunotherapy bexmarilimab has been granted orphan drug designation from the FDA for patients with myelodysplastic syndromes.

Rusfertide outperformed placebo in polycythemia vera, meeting all primary and secondary end points in the phase 3 VERIFY study.

The first patient with myelodysplastic syndrome has received iadademstat plus azacitidine in a phase 1 trial at the Medical College of Wisconsin.

Hany Elmariah, MD, discussed the safety profile of fedratinib and its evolving role in the post-transplant setting for patients with myeloproliferative neoplasms.